HER2+ early breast cancer: biosimilar ABP 980 as safe, effective as trastuzumab in LILAC trial

  • Lancet Oncol

  • curated by Miriam Davis, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Trastuzumab biosimilar ABP 980 is as safe and effective as trastuzumab for early human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

Why this matters

  • Trastuzumab biosimilars have the potential to cut costs and expand access to care.

Study design

  • Randomized, controlled, double-blind, multicenter, phase 3 clinical trial of ABP 980 (n=364) or trastuzumab (n=361).
  • Trial had 3 phases: neoadjuvant therapy, surgery, and adjuvant therapy.
    • Neoadjuvant therapy: 8 mg/kg of ABP 980 or trastuzumab in loading dose with paclitaxel, followed by 3 cycles of 6 mg/kg of ABP 980 or trastuzumab with paclitaxel every 3 weeks in 30 minute intravenous infusions;
    • Surgery: 3-7 weeks after completion of neoadjuvant therapy;
    • Adjuvant therapy: ABP 980 or trastuzumab every 3 weeks for up to 1 year.
  • Funding: Amgen.

Key results

  • Pathologic complete response (pCR) attained (in local laboratory review) by 48% of ABP 980 group and 41% of trastuzumab group, with risk difference of 7.3% (90% CI, 1.2-13.4) and risk ratio (RR) of 1.188 (90% CI, 1.033-1.366), indicating noninferiority of lower boundaries of 90% CIs for risk difference and RR, and upper boundaries exceeding predefined equivalence margins of 13% and 1.318, respectively.
  • No difference in grade 3 or worse adverse events was seen.

Limitations

  • Locally reviewed pCR.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit